The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat Topic 5/18: What’s PFS Got to Do with It?
- #LCSM Chat Topic 5/4 — The PDQ on MTBs: Why are multidisciplinary tumor boards important in #lungcancer?
- #LCSM Chat Topic 4/20: Online Cancer Education: What are the Best Tools & Current Limitations?
- #LCSM Chat Topic 4/6: Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?
- #LCSM Chat Topic 3/23: What Is a High-Value Cancer Drug?
#ASCO16 #LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment PCORI Screening self-advocacy shared decision making trials World Cancer Day